Commonly Used Opioids in Pain Management Market 2016 Sep 2016 | Page 4

Pain Management- New Discoveries And Treatment Options In Abuse Deterrent Era New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years. US Opioids market is of $8b in size and of which extended release formulations contribute 50%. ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of opioid market in US and Europe in coming years. Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioids use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management. Inquire for Discount http://www.reportsnreports.com/contacts/discount.aspx?name=679333. Order this report by calling [phone] or Send an email to [email protected] with your contact details and questions if any. © ReportsnReports.com / Contact [email protected] 4